Tesamorelin vs CJC-1295: Two Ways to Stabilise GHRH

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

Tesamorelin and CJC-1295 solve the same problem in opposite ways. Native GHRH is destroyed within minutes, so both molecules are engineered to survive longer. Tesamorelin keeps the whole 44-residue hormone and caps its N-terminus. CJC-1295 keeps only the active 1–29 fragment, substitutes four residues, and (in the DAC version) attaches itself to albumin. The results are very different time courses.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

Summary card of the comparison table from the tesamorelin vs cjc 1295 research article — Summary of the table in this article; the cited sources are listed under References.

Key points

Same receptor: GHRH-R on pituitary somatotrophs.
Tesamorelin: full length, chemically capped, daily administration in trials.
CJC-1295 with DAC: shortened and substituted, half-life 5.8–8.1 days.
Tesamorelin has phase 3 data; CJC-1295 has healthy-volunteer studies.
No head-to-head comparison has been published.

Side-by-side

	Tesamorelin	CJC-1295 (with DAC)
Backbone	GHRH(1-44)-NH₂	GHRH(1-29)-NH₂
Modifications	trans-3-hexenoyl on Tyr1	D-Ala2, Gln8, Ala15, Leu27 + DAC linker
Molecular weight	~5136 g/mol	~3647 g/mol
How it resists degradation	Blocked N-terminus	Substituted cleavage and oxidation sites; albumin binding
Half-life	Short enough for daily use in trials	5.8–8.1 days
Key human data	412-patient phase 3; visceral fat −15.2%, IGF-I +81%	Two ascending-dose studies in healthy adults
Oxidation-prone Met27	Present	Replaced by Leu

Both are available for research: tesamorelin and CJC-1295 (no DAC), with a separate DAC version listed.

Two design philosophies

GHRH’s first 29 residues contain everything needed to activate the receptor, which signals mainly through cAMP (Halmos et al., 2025). From there the designers diverged.

Tesamorelin keeps the natural sequence intact and adds a single chemical cap. The molecule the receptor sees is as close to GHRH as a stabilised analogue can be. The cost is size: at 5.1 kDa it is harder to synthesise and purify.
CJC-1295 engineers the fragment. Four substitutions remove weak points (DPP-4 cleavage at position 2, deamidation at 8, oxidation at 27). The DAC version then adds a maleimide linker that binds albumin’s free cysteine, which is what produces the week-long half-life.

What that means for GH patterns

Observation	Compound	Study
Single dose raised GH 2–10× for ≥6 days; IGF-I 1.5–3× for 9–11 days; multiple doses kept IGF-I above baseline for 28 days	CJC-1295 with DAC	Teichman et al., 2006
Pulsatility preserved one week after a dose; trough GH up 7.5×, mean GH up 46%, IGF-I up 45%	CJC-1295 with DAC	Ionescu et al., 2006
IGF-I +81% vs −5% placebo over 26 weeks of daily administration	Tesamorelin	Falutz et al., 2007
Visceral fat reduction maintained to week 52; re-accumulated after stopping	Tesamorelin	Dhillon, 2011

The CJC-1295 data describe what continuous GHRH-receptor stimulation does to the GH profile; the tesamorelin data describe what months of daily stimulation do to a clinical endpoint. They answer different questions.

Practical differences in the lab

Aspect	Tesamorelin	CJC-1295
Dissolution	Larger peptide; allow extra gentle swirling	Dissolves readily
Oxidation risk	Met27 present; limit air and light	Met replaced; lower risk
Reactive group	None	DAC version has a maleimide: avoid thiol-containing buffers
Identity check	MS: ~5136 vs ~3647 (DAC) vs ~3368 (no DAC) g/mol — all clearly distinguishable

Both are covered by validated LC-MS/MS anti-doping methods, with 19 characterised in vitro metabolites across the GHRH analogue family and detection limits generally at or below 1 ng/mL (Memdouh et al., 2021).

Which to choose for an experiment

Research aim	Better fit	Reason
Model GHRH signalling with a near-native ligand	Tesamorelin	Full 44-residue sequence, only the N-terminus modified
Study sustained receptor occupancy over days	CJC-1295 with DAC	Week-long half-life from albumin binding
Model short, pulse-like GHRH exposure	CJC-1295 without DAC	No albumin binder, so exposure is brief
Combine with a ghrelin-receptor agonist	CJC-1295 without DAC	Time course matches short-acting secretagogues
Compare against a compound with clinical endpoints	Tesamorelin	Phase 3 data in a defined population

A practical point for anyone buying either: because the three CJC-1295 forms share a name, the certificate of analysis matters more here than for most peptides. Confirm from the mass whether a vial holds the DAC or the no-DAC version before planning a time course around it.

Open questions

Does the longer tesamorelin sequence contribute to receptor binding beyond what GHRH(1-29) provides?
Does week-long GHRH-receptor stimulation eventually desensitise the receptor?
How do the two compare on IGF-I per unit of GH exposure?

Frequently asked questions

What is the difference between tesamorelin and CJC-1295?

Both are GHRH-receptor agonists, but they are stabilised differently. Tesamorelin is full-length GHRH(1-44) with a trans-3-hexenoyl group on the N-terminus. CJC-1295 is the shorter GHRH(1-29) with four amino acid substitutions, and the DAC version additionally binds albumin.

Which lasts longer?

CJC-1295 with DAC, by a wide margin: its estimated half-life in healthy adults was 5.8–8.1 days. Tesamorelin was given once daily in its phase 3 trials.

Which has more clinical evidence?

Tesamorelin. It has two 26-week phase 3 trials and a licensed indication. CJC-1295’s human data are two ascending-dose studies in healthy volunteers.

Do they act on the same receptor?

Yes, both activate the GHRH receptor on pituitary somatotrophs. The difference lies in structure and duration, not in target.

Can the two be compared directly?

Not from published data. No head-to-head trial exists, and the studies used different populations, durations and endpoints.